Alexion Pharmaceuticals, Incorporated (ALXN)
ALXN Stock Report
Sharpen Your Investing
- Access to over 5,000 stock reports
- Portfolio Analytics and Tracking
- Business Television Tracking
- CNBC and Fox Business Show Recaps
Key Fundamentals
| Price (3/19 4:00PM) | $54.26 |
|---|---|
| Volume (3/19 4:00PM) | 838,202 |
| Last Close Price | $53.25 |
| 10 Day Average Volume | 496,500 |
| 13 Week Price Range | $44.86 - $54.15 |
| 52 Week Price Range | $32.26 - $54.15 |
| LTM Revenue | $386.8 Million |
| Shares Outstanding (12/2009) | 89.1 Million |
| Market Capitalization | $4.7 Billion |
| Shares Held By Institutions | 94.7 Million |
| Institutional Holders | 312 |
| % Shares Held By Institutions | % |
| Earnings Per Share (EPS) | $3.26 |
| P/E Ratio | 16.30 |
| Book Value Per Share | $7.72 |
| Gross Margin | 91.60% |
| Annual Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Beta | 0.61 |
| Fiscal Year Ends | December |
About Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Incorporated is considered to operate in the Healthcare sector. They specifically operate in the Drug Manufacturers/Other business segment contained within the Drugs industry.
A biopharmaceutical company, which is engaged in the discovery, development and delivery of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states.
News Breaking on Alexion Pharmaceuticals, Incorporated on Inside Track With Deidre Bolton and Erik Schatzker
The latest news from Inside Track With Deidre Bolton and Erik Schatzker on ALXN is available through Ockham's news analytics platform RazorWire.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, ALXN has been less covered in the news compared to the rest of our universe of stocks. The crowd at The Motley Fool does not like ALXN and believes that it will Underperform. We consider ALXN as Undervalued at the current price of $52.85. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise.
“… Two names to watch, ALEXION PHARMACEUTICALS. Growth is underestimated and likely upside to 2010 earnings. Another name, pharmaceuticals. …”
Alexion Pharmaceuticals, Incorporated Was Talked About by Imus In The Morning
As always, the latest news on ALXN is available to Ockham clients through RazorWire, and it was mentioned recently on Imus In The Morning.
Based on our methodology, Alexion Pharmaceuticals, Incorporated should hold some appeal to value investors as we view it as Undervalued. We noticed recently that in comparison to all other stocks we analyze in the news; ALXN has received less coverage from the financial media in business television and blogs. While bearish sentiment on a stock is not always a bad thing, it is something you need to be aware of. The Motley Fool survey of crowd sentiment shows that many investors believe this stock will underperform.
“… Two names to watch, ALEXION PHARMACEUTICALS. Growth is underestimated and likely upside to 2010 earnings. Another name, pharmaceuticals. …”
National Post Network Blogs Picks Up on ALXN News After Six Months
ALXN has not been a media darling in the last six months, but they have started to pay attention as you can see by the story on National Post Network Blogs.
At present, Ockham has a valuation stance of Undervalued on ALXN, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue. When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Alexion Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. Interestingly, overall sentiment looks bearish according to the Motley Fool's CAPS survey, as most of their users see Alexion Pharmaceuticals, Incorporated underperforming.
“… of the Biotech sector with a series of Overweight stock recommendations including Rigel Pharmaceutical, Adrea Biosciences, Human Genome, Gilead, ALEXION PHARMACEUTICALS and ... …”
Alexion Pharmaceuticals, Incorporated (ALXN) Discussed on CNBC's Fast Money
Alexion Pharmaceuticals, Incorporated is in the news. Find out how this impacts ALXN trading on Ockham Research.
Not only the clinical outlooks but also the outlook for the monies that are coming in. And if investors know that the government is putting up $10 billion, not of course just to ALEXION but to a host of stem cell stocks, i'd be in there. But then watch those clinical stocks, too, melissa, because I think there's a real play there as well. >> okay. Appreciate it.
“… ose clinical stocks, too, melissa, because I think there's a real play there as well. >> okay. Appreciate it. …”
Alexion Pharmaceuticals, Incorporated (ALXN) Discussed on CNBC's Fast Money
Alexion Pharmaceuticals, Incorporated is in the news. Find out how this impacts ALXN trading on Ockham Research.
Partners that might end up being owners if these clinical results so both those two stocks are stocks in the stem cell space I like, and I own them both. >> ALEXION you mentioned earnings this week. Do you get in ahead of the is there an opportunity here? >> I do think there is because just as you mentioned with 10 billion going to be spent in the sector I think these guys will
“… >> I do think there is because just as you mentioned with 10 billion going to be spent in the sector I think these guys will …”
Alexion Pharmaceuticals, Incorporated (ALXN) Discussed on CNBC's Fast Money
Alexion Pharmaceuticals, Incorporated is in the news. Find out how this impacts ALXN trading on Ockham Research.
The co-founder of optionmonster.Com jon najarian. Nice to see you. >> great to be here. Thank you. >> give smus trades. >> ALEXION pharmaceutical. I own a host of these stocks. ALEXION has earnings due thursday of this week, melissa. And they're everything from autoimmune disease, cancer treatments, hematologic as well as neurologic treatments of
“… g from autoimmune disease, cancer treatments, hematologic as well as neurologic treatments of …”